Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Jeffrey Swigris to Idiopathic Pulmonary Fibrosis

This is a "connection" page, showing publications Jeffrey Swigris has written about Idiopathic Pulmonary Fibrosis.

 
Connection Strength
  
 
 
12.800
  
  1. Swigris JJ, Bushnell DM, Rohr K, Mueller H, Baldwin M, Inoue Y. Responsiveness and meaningful change thresholds of the Living with Pulmonary Fibrosis (L-PF) questionnaire Dyspnoea and Cough scores in patients with progressive fibrosing interstitial lung diseases. BMJ Open Respir Res. 2022 03; 9(1).
    View in: PubMed
    Score: 0.459
  2. Wakwaya Y, Ramdurai D, Swigris JJ. Managing Cough in Idiopathic Pulmonary Fibrosis. Chest. 2021 11; 160(5):1774-1782.
    View in: PubMed
    Score: 0.438
  3. Maher TM, Costabel U, Glassberg MK, Kondoh Y, Ogura T, Scholand MB, Kardatzke D, Howard M, Olsson J, Neighbors M, Belloni P, Swigris JJ. Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2021 02; 57(2).
    View in: PubMed
    Score: 0.426
  4. Swigris JJ, Andrae DA, Churney T, Johnson N, Scholand MB, White ES, Matsui A, Raimundo K, Evans CJ. Development and Initial Validation Analyses of the Living with Idiopathic Pulmonary Fibrosis Questionnaire. Am J Respir Crit Care Med. 2020 12 15; 202(12):1689-1697.
    View in: PubMed
    Score: 0.422
  5. Antoniou K, Kamekis A, Symvoulakis EK, Kokosi M, Swigris JJ. Burden of idiopathic pulmonary fibrosis on patients' emotional well being and quality of life: a literature review. Curr Opin Pulm Med. 2020 09; 26(5):457-463.
    View in: PubMed
    Score: 0.414
  6. Swigris JJ. The 4-min mile and supplemental oxygen in IPF. Respirology. 2020 11; 25(11):1114-1115.
    View in: PubMed
    Score: 0.408
  7. Kreuter M, Wuyts WA, Wijsenbeek M, Bajwah S, Maher TM, Stowasser S, Male N, Stansen W, Schoof N, Orsatti L, Swigris J. Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS? trials. Respir Res. 2020 Jan 30; 21(1):36.
    View in: PubMed
    Score: 0.397
  8. Ramadurai D, Corder S, Churney T, Graney B, Harshman A, Meadows S, Swigris JJ. Idiopathic pulmonary fibrosis: Educational needs of health-care providers, patients, and caregivers. Chron Respir Dis. 2019 Jan-Dec; 16:1479973119858961.
    View in: PubMed
    Score: 0.369
  9. Swigris JJ. Towards a refined definition of combined pulmonary fibrosis and emphysema. Respirology. 2019 01; 24(1):9-10.
    View in: PubMed
    Score: 0.363
  10. Swigris JJ, Esser D, Wilson H, Conoscenti CS, Schmidt H, Stansen W, Leidy NK, Brown KK. Psychometric properties of the St George's Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2017 01; 49(1).
    View in: PubMed
    Score: 0.322
  11. Albera C, Costabel U, Fagan EA, Glassberg MK, Gorina E, Lancaster L, Lederer DJ, Nathan SD, Spirig D, Swigris JJ. Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. Eur Respir J. 2016 09; 48(3):843-51.
    View in: PubMed
    Score: 0.312
  12. Lederer DJ, Swigris JJ. Idiopathic Pulmonary Fibrosis on the Internet. Let's Calm the Sea of (Mis)information. Am J Respir Crit Care Med. 2016 07 15; 194(2):134-6.
    View in: PubMed
    Score: 0.311
  13. Russell AM, Swigris JJ. What's it like to live with idiopathic pulmonary fibrosis? Ask the experts. Eur Respir J. 2016 05; 47(5):1324-6.
    View in: PubMed
    Score: 0.306
  14. Raimundo K, Chang E, Broder MS, Alexander K, Zazzali J, Swigris JJ. Clinical and economic burden of idiopathic pulmonary fibrosis: a retrospective cohort study. BMC Pulm Med. 2016 Jan 05; 16:2.
    View in: PubMed
    Score: 0.300
  15. Solomon JJ, Chung JH, Cosgrove GP, Demoruelle MK, Fernandez-Perez ER, Fischer A, Frankel SK, Hobbs SB, Huie TJ, Ketzer J, Mannina A, Olson AL, Russell G, Tsuchiya Y, Yunt ZX, Zelarney PT, Brown KK, Swigris JJ. Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2016 Feb; 47(2):588-96.
    View in: PubMed
    Score: 0.297
  16. Russell AM, Sprangers MA, Wibberley S, Snell N, Rose DM, Swigris JJ. The need for patient-centred clinical research in idiopathic pulmonary fibrosis. BMC Med. 2015 Sep 24; 13:240.
    View in: PubMed
    Score: 0.294
  17. Strand MJ, Sprunger D, Cosgrove GP, Fernandez-Perez ER, Frankel SK, Huie TJ, Olson AL, Solomon J, Brown KK, Swigris JJ. Pulmonary function and survival in idiopathic vs secondary usual interstitial pneumonia. Chest. 2014 Sep; 146(3):775-785.
    View in: PubMed
    Score: 0.273
  18. Swigris JJ, Esser D, Conoscenti CS, Brown KK. The psychometric properties of the St George's Respiratory Questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: a literature review. Health Qual Life Outcomes. 2014 Aug 20; 12:124.
    View in: PubMed
    Score: 0.272
  19. Belkin A, Swigris JJ. Patient expectations and experiences in idiopathic pulmonary fibrosis: implications of patient surveys for improved care. Expert Rev Respir Med. 2014 Apr; 8(2):173-8.
    View in: PubMed
    Score: 0.262
  20. Swigris JJ, Streiner DL, Brown KK, Belkin A, Green KE, Wamboldt FS. Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis. Respir Med. 2014 Jan; 108(1):181-8.
    View in: PubMed
    Score: 0.260
  21. Belkin A, Swigris JJ. Health-related quality of life in idiopathic pulmonary fibrosis: where are we now? Curr Opin Pulm Med. 2013 Sep; 19(5):474-9.
    View in: PubMed
    Score: 0.255
  22. Swigris JJ, Brown KK, Belkin A. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis. Ann Intern Med. 2013 Mar 19; 158(6):498.
    View in: PubMed
    Score: 0.247
  23. Swigris JJ, Fairclough D. Patient-reported outcomes in idiopathic pulmonary fibrosis research. Chest. 2012 Aug; 142(2):291-297.
    View in: PubMed
    Score: 0.236
  24. Swigris JJ, Han M, Vij R, Noth I, Eisenstein EL, Anstrom KJ, Brown KK, Fairclough D. The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis. Respir Med. 2012 Oct; 106(10):1447-55.
    View in: PubMed
    Score: 0.236
  25. Olson AL, Swigris JJ. Idiopathic pulmonary fibrosis: diagnosis and epidemiology. Clin Chest Med. 2012 Mar; 33(1):41-50.
    View in: PubMed
    Score: 0.230
  26. Swigris JJ, Olson AL, Huie TJ, Fernandez-Perez ER, Solomon J, Sprunger D, Brown KK. Ethnic and racial differences in the presence of idiopathic pulmonary fibrosis at death. Respir Med. 2012 Apr; 106(4):588-93.
    View in: PubMed
    Score: 0.228
  27. Swigris JJ, Olson AL, Shlobin OA, Ahmad S, Brown KK, Nathan SD. Heart rate recovery after six-minute walk test predicts pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respirology. 2011 Apr; 16(3):439-45.
    View in: PubMed
    Score: 0.215
  28. Yorke J, Jones PW, Swigris JJ. Development and validity testing of an IPF-specific version of the St George's Respiratory Questionnaire. Thorax. 2010 Oct; 65(10):921-6.
    View in: PubMed
    Score: 0.208
  29. Swigris JJ, Wilson SR, Green KE, Sprunger DB, Brown KK, Wamboldt FS. Development of the ATAQ-IPF: a tool to assess quality of life in IPF. Health Qual Life Outcomes. 2010 Jul 31; 8:77.
    View in: PubMed
    Score: 0.206
  30. Swigris JJ, Wamboldt FS, Behr J, du Bois RM, King TE, Raghu G, Brown KK. The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. Thorax. 2010 Feb; 65(2):173-7.
    View in: PubMed
    Score: 0.197
  31. Swigris JJ, Brown KK, Behr J, du Bois RM, King TE, Raghu G, Wamboldt FS. The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med. 2010 Feb; 104(2):296-304.
    View in: PubMed
    Score: 0.194
  32. Swigris JJ, Swick J, Wamboldt FS, Sprunger D, du Bois R, Fischer A, Cosgrove GP, Frankel SK, Fernandez-Perez ER, Kervitsky D, Brown KK. Heart rate recovery after 6-min walk test predicts survival in patients with idiopathic pulmonary fibrosis. Chest. 2009 Sep; 136(3):841-848.
    View in: PubMed
    Score: 0.188
  33. Swigris JJ, Brown KK, Make BJ, Wamboldt FS. Pulmonary rehabilitation in idiopathic pulmonary fibrosis: a call for continued investigation. Respir Med. 2008 Dec; 102(12):1675-80.
    View in: PubMed
    Score: 0.181
  34. Kam MLW, Tjong ELH, Chaudhary S, Koelsch TL, Pryor JB, Koslow M, Mohning MP, Solomon JJ, Huie TJ, Swigris JJ, Fern?ndez P?rez ER. Development and validation of a clinical, CT, genomic classifier and BAL scoring system for diagnosing idiopathic pulmonary fibrosis. Eur Respir J. 2025 Mar; 65(3).
    View in: PubMed
    Score: 0.142
  35. Raghu G, Ghazipura M, Fleming TR, Aronson KI, Behr J, Brown KK, Flaherty KR, Kazerooni EA, Maher TM, Richeldi L, Lasky JA, Swigris JJ, Busch R, Garrard L, Ahn DH, Li J, Puthawala K, Rodal G, Seymour S, Weir N, Danoff SK, Ettinger N, Goldin J, Glassberg MK, Kawano-Dourado L, Khalil N, Lancaster L, Lynch DA, Mageto Y, Noth I, Shore JE, Wijsenbeek M, Brown R, Grogan D, Ivey D, Golinska P, Karimi-Shah B, Martinez FJ. Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the National Institutes of Health, a Patient Advocacy Organization, and a Regulatory Agency. Am J Respir Crit Care Med. 2024 03 15; 209(6):647-669.
    View in: PubMed
    Score: 0.132
  36. Oh AS, Lynch DA, Swigris JJ, Baraghoshi D, Dyer DS, Hale VA, Koelsch TL, Marrocchio C, Parker KN, Teague SD, Flaherty KR, Humphries SM. Deep Learning-based Fibrosis Extent on Computed Tomography Predicts Outcome of Fibrosing Interstitial Lung Disease Independent of Visually Assessed Computed Tomography Pattern. Ann Am Thorac Soc. 2024 Feb; 21(2):218-227.
    View in: PubMed
    Score: 0.131
  37. Wijsenbeek M, Swigris JJ, Inoue Y, Kreuter M, Maher TM, Suda T, Baldwin M, Mueller H, Rohr KB, Flaherty KR. Effects of nintedanib on symptoms in patients with progressive pulmonary fibrosis. Eur Respir J. 2024 Feb; 63(2).
    View in: PubMed
    Score: 0.131
  38. Peljto AL, Blumhagen RZ, Walts AD, Cardwell J, Powers J, Corte TJ, Dickinson JL, Glaspole I, Moodley YP, Vasakova MK, Bendstrup E, Davidsen JR, Borie R, Crestani B, Dieude P, Bonella F, Costabel U, Gudmundsson G, Donnelly SC, Egan J, Henry MT, Keane MP, Kennedy MP, McCarthy C, McElroy AN, Olaniyi JA, O'Reilly KMA, Richeldi L, Leone PM, Poletti V, Puppo F, Tomassetti S, Luzzi V, Kokturk N, Mogulkoc N, Fiddler CA, Hirani N, Jenkins RG, Maher TM, Molyneaux PL, Parfrey H, Braybrooke R, Blackwell TS, Jackson PD, Nathan SD, Porteous MK, Brown KK, Christie JD, Collard HR, Eickelberg O, Foster EE, Gibson KF, Glassberg M, Kass DJ, Kropski JA, Lederer D, Linderholm AL, Loyd J, Mathai SK, Montesi SB, Noth I, Oldham JM, Palmisciano AJ, Reichner CA, Rojas M, Roman J, Schluger N, Shea BS, Swigris JJ, Wolters PJ, Zhang Y, Prele CMA, Enghelmayer JI, Otaola M, Ryerson CJ, Salinas M, Sterclova M, Gebremariam TH, Myll?rniemi M, Carbone RG, Furusawa H, Hirose M, Inoue Y, Miyazaki Y, Ohta K, Ohta S, Okamoto T, Kim DS, Pardo A, Selman M, Aranda AU, Park MS, Park JS, Song JW, Molina-Molina M, Planas-Cerezales L, Westergren-Thorsson G, Smith AV, Manichaikul AW, Kim JS, Rich SS, Oelsner EC, Barr RG, Rotter JI, Dupuis J, O'Connor G, Vasan RS, Cho MH, Silverman EK, Schwarz MI, Steele MP, Lee JS, Yang IV, Fingerlin TE, Schwartz DA. Idiopathic Pulmonary Fibrosis Is Associated with Common Genetic Variants and Limited Rare Variants. Am J Respir Crit Care Med. 2023 05 01; 207(9):1194-1202.
    View in: PubMed
    Score: 0.124
  39. Fern?ndez P?rez ER, Crooks JL, Lynch DA, Humphries SM, Koelsch TL, Swigris JJ, Solomon JJ, Mohning MP, Groshong SD, Fier K. Pirfenidone in fibrotic hypersensitivity pneumonitis: a double-blind, randomised clinical trial of efficacy and safety. Thorax. 2023 11; 78(11):1097-1104.
    View in: PubMed
    Score: 0.124
  40. Wilson TM, Solomon JJ, Humphries SM, Swigris JJ, Ahmed F, Wang H, Darrah E, Demoruelle MK. Serum antibodies to peptidylarginine deiminase-4 in rheumatoid arthritis associated-interstitial lung disease are associated with decreased lung fibrosis and improved survival. Am J Med Sci. 2023 06; 365(6):480-487.
    View in: PubMed
    Score: 0.123
  41. Corte TJ, Lancaster L, Swigris JJ, Maher TM, Goldin JG, Palmer SM, Suda T, Ogura T, Minnich A, Zhan X, Tirucherai GS, Elpers B, Xiao H, Watanabe H, Smith RA, Charles ED, Fischer A. Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD). BMJ Open Respir Res. 2021 Dec; 8(1).
    View in: PubMed
    Score: 0.113
  42. Guler SA, Lindell KO, Swigris J, Ryerson CJ. Nondrug Treatments for Idiopathic Pulmonary Fibrosis: IPF Part 3. Am J Respir Crit Care Med. 2021 02 15; 203(4):P10-P11.
    View in: PubMed
    Score: 0.107
  43. Guler SA, Lindell KO, Swigris J, Ryerson CJ. Medications for Idiopathic Pulmonary Fibrosis: IPF Part 2. Am J Respir Crit Care Med. 2021 02 01; 203(3):P7-P8.
    View in: PubMed
    Score: 0.106
  44. Guler SA, Lindell KO, Swigris J, Ryerson CJ. What Is Idiopathic Pulmonary Fibrosis? IPF Part 1. Am J Respir Crit Care Med. 2021 01 15; 203(2):P5-P6.
    View in: PubMed
    Score: 0.106
  45. Solomon JJ, Matson S, Kelmenson LB, Chung JH, Hobbs SB, Rosas IO, Dellaripa PF, Doyle TJ, Poli S, Esposito AJ, Visser A, Marin AI, Amigues I, Fern?ndez P?rez ER, Brown KK, Mahler M, Heinz D, Cool C, Deane KD, Swigris JJ, Demoruelle MK. IgA Antibodies Directed Against Citrullinated Protein Antigens Are Elevated in Patients With Idiopathic Pulmonary Fibrosis. Chest. 2020 06; 157(6):1513-1521.
    View in: PubMed
    Score: 0.099
  46. Moore C, Blumhagen RZ, Yang IV, Walts A, Powers J, Walker T, Bishop M, Russell P, Vestal B, Cardwell J, Markin CR, Mathai SK, Schwarz MI, Steele MP, Lee J, Brown KK, Loyd JE, Crapo JD, Silverman EK, Cho MH, James JA, Guthridge JM, Cogan JD, Kropski JA, Swigris JJ, Bair C, Kim DS, Ji W, Kim H, Song JW, Maier LA, Pacheco KA, Hirani N, Poon AS, Li F, Jenkins RG, Braybrooke R, Saini G, Maher TM, Molyneaux PL, Saunders P, Zhang Y, Gibson KF, Kass DJ, Rojas M, Sembrat J, Wolters PJ, Collard HR, Sundy JS, O'Riordan T, Strek ME, Noth I, Ma SF, Porteous MK, Kreider ME, Patel NB, Inoue Y, Hirose M, Arai T, Akagawa S, Eickelberg O, Fernandez IE, Behr J, Mogulkoc N, Corte TJ, Glaspole I, Tomassetti S, Ravaglia C, Poletti V, Crestani B, Borie R, Kannengiesser C, Parfrey H, Fiddler C, Rassl D, Molina-Molina M, Machahua C, Worboys AM, Gudmundsson G, Isaksson HJ, Lederer DJ, Podolanczuk AJ, Montesi SB, Bendstrup E, Danchel V, Selman M, Pardo A, Henry MT, Keane MP, Doran P, Va??kov? M, Sterclova M, Ryerson CJ, Wilcox PG, Okamoto T, Furusawa H, Miyazaki Y, Laurent G, Baltic S, Prele C, Moodley Y, Shea BS, Ohta K, Suzukawa M, Narumoto O, Nathan SD, Venuto DC, Woldehanna ML, Kokturk N, de Andrade JA, Luckhardt T, Kulkarni T, Bonella F, Donnelly SC, McElroy A, Armstong ME, Aranda A, Carbone RG, Puppo F, Beckman KB, Nickerson DA, Fingerlin TE, Schwartz DA. Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2019 07 15; 200(2):199-208.
    View in: PubMed
    Score: 0.096
  47. Kreuter M, Swigris J, Pittrow D, Geier S, Klotsche J, Prasse A, Wirtz H, Koschel D, Andreas S, Claussen M, Groh? C, Wilkens H, Hagmeyer L, Skowasch D, Meyer JF, Kirschner J, Gl?ser S, Kahn N, Welte T, Neurohr C, Schwaiblmair M, Held M, Bahmer T, Oqueka T, Frankenberger M, Behr J. The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry. Respir Res. 2019 Mar 15; 20(1):59.
    View in: PubMed
    Score: 0.093
  48. Humphries SM, Swigris JJ, Brown KK, Strand M, Gong Q, Sundy JS, Raghu G, Schwarz MI, Flaherty KR, Sood R, O'Riordan TG, Lynch DA. Quantitative high-resolution computed tomography fibrosis score: performance characteristics in idiopathic pulmonary fibrosis. Eur Respir J. 2018 09; 52(3).
    View in: PubMed
    Score: 0.090
  49. Maher TM, Swigris JJ, Kreuter M, Wijsenbeek M, Cassidy N, Ireland L, Axmann J, Nathan SD. Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views. Respiration. 2018; 96(6):514-524.
    View in: PubMed
    Score: 0.090
  50. Martinez FJ, Collard HR, Pardo A, Raghu G, Richeldi L, Selman M, Swigris JJ, Taniguchi H, Wells AU. Idiopathic pulmonary fibrosis. Nat Rev Dis Primers. 2017 Oct 20; 3:17074.
    View in: PubMed
    Score: 0.085
  51. Ley B, Swigris J, Day BM, Stauffer JL, Raimundo K, Chou W, Collard HR. Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2017 09 15; 196(6):756-761.
    View in: PubMed
    Score: 0.084
  52. Kreuter M, Swigris J, Pittrow D, Geier S, Klotsche J, Prasse A, Wirtz H, Koschel D, Andreas S, Claussen M, Groh? C, Wilkens H, Hagmeyer L, Skowasch D, Meyer JF, Kirschner J, Gl?ser S, Herth FJF, Welte T, Neurohr C, Schwaiblmair M, Held M, Bahmer T, Frankenberger M, Behr J. Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry. Respir Res. 2017 07 14; 18(1):139.
    View in: PubMed
    Score: 0.083
  53. Natalini JG, Swigris JJ, Morisset J, Elicker BM, Jones KD, Fischer A, Collard HR, Lee JS. Understanding the determinants of health-related quality of life in rheumatoid arthritis-associated interstitial lung disease. Respir Med. 2017 06; 127:1-6.
    View in: PubMed
    Score: 0.082
  54. Yunt ZX, Chung JH, Hobbs S, Fernandez-Perez ER, Olson AL, Huie TJ, Keith RC, Janssen WJ, Goldstein BL, Lynch DA, Brown KK, Swigris JJ, Solomon JJ. High resolution computed tomography pattern of usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease: Relationship to survival. Respir Med. 2017 05; 126:100-104.
    View in: PubMed
    Score: 0.082
  55. Nathan SD, Albera C, Bradford WZ, Costabel U, Glaspole I, Glassberg MK, Kardatzke DR, Daigl M, Kirchgaessler KU, Lancaster LH, Lederer DJ, Pereira CA, Swigris JJ, Valeyre D, Noble PW. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir Med. 2017 01; 5(1):33-41.
    View in: PubMed
    Score: 0.080
  56. Nathan SD, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Glasscock KF, King TE, Lancaster L, Lederer DJ, Lin Z, Pereira CA, Swigris JJ, Valeyre D, Noble PW, Wells AU. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax. 2016 05; 71(5):429-35.
    View in: PubMed
    Score: 0.076
  57. Yount SE, Beaumont JL, Chen SY, Kaiser K, Wortman K, Van Brunt DL, Swigris J, Cella D. Health-Related Quality of Life in Patients with Idiopathic Pulmonary Fibrosis. Lung. 2016 Apr; 194(2):227-34.
    View in: PubMed
    Score: 0.075
  58. Noble PW, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Lancaster L, Lederer DJ, Leff JA, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, King TE. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J. 2016 Jan; 47(1):243-53.
    View in: PubMed
    Score: 0.074
  59. Lederer DJ, Bradford WZ, Fagan EA, Glaspole I, Glassberg MK, Glasscock KF, Kardatzke D, King TE, Lancaster LH, Nathan SD, Pereira CA, Sahn SA, Swigris JJ, Noble PW. Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis. Chest. 2015 Jul; 148(1):196-201.
    View in: PubMed
    Score: 0.072
  60. Strookappe B, Elfferich M, Swigris J, Verschoof A, Veschakelen J, Knevel T, Drent M. Benefits of physical training in patients with idiopathic or end-stage sarcoidosis-related pulmonary fibrosis: a pilot study. Sarcoidosis Vasc Diffuse Lung Dis. 2015 Jun 22; 32(1):43-52.
    View in: PubMed
    Score: 0.072
  61. Olson AL, Swigris JJ, Belkin A, Hannen L, Yagihashi K, Schenkman M, Brown KK. Physical functional capacity in idiopathic pulmonary fibrosis: performance characteristics of the continuous-scale physical function performance test. Expert Rev Respir Med. 2015 Jun; 9(3):361-7.
    View in: PubMed
    Score: 0.071
  62. King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014 May 29; 370(22):2083-92.
    View in: PubMed
    Score: 0.067
  63. Saketkoo LA, Mittoo S, Huscher D, Khanna D, Dellaripa PF, Distler O, Flaherty KR, Frankel S, Oddis CV, Denton CP, Fischer A, Kowal-Bielecka OM, LeSage D, Merkel PA, Phillips K, Pittrow D, Swigris J, Antoniou K, Baughman RP, Castelino FV, Christmann RB, Christopher-Stine L, Collard HR, Cottin V, Danoff S, Highland KB, Hummers L, Shah AA, Kim DS, Lynch DA, Miller FW, Proudman SM, Richeldi L, Ryu JH, Sandorfi N, Sarver C, Wells AU, Strand V, Matteson EL, Brown KK, Seibold JR. Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. Thorax. 2014 May; 69(5):428-36.
    View in: PubMed
    Score: 0.065
  64. Ribeiro Neto ML, Swigris JJ, Culver DA. Idiopathic pulmonary fibrosis or not: antibiotic prophylaxis for all patients on immunosuppressants. Thorax. 2013 Sep; 68(9):883-4.
    View in: PubMed
    Score: 0.062
  65. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE, Kondoh Y, Myers J, M?ller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Sch?nemann HJ. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011 Mar 15; 183(6):788-824.
    View in: PubMed
    Score: 0.054
  66. Han MK, Swigris J, Liu L, Bartholmai B, Murray S, Giardino N, Thompson B, Frederick M, Li D, Schwarz M, Limper A, Flaherty K, Martinez FJ. Gender influences Health-Related Quality of Life in IPF. Respir Med. 2010 May; 104(5):724-30.
    View in: PubMed
    Score: 0.049
  67. Humphries SM, Thieke D, Baraghoshi D, Strand MJ, Swigris JJ, Chae KJ, Hwang HJ, Oh AS, Flaherty KR, Adegunsoye A, Jablonski R, Lee CT, Husain AN, Chung JH, Strek ME, Lynch DA. Deep Learning Classification of Usual Interstitial Pneumonia Predicts Outcomes. Am J Respir Crit Care Med. 2024 05 01; 209(9):1121-1131.
    View in: PubMed
    Score: 0.033
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)